Advertisement
Abstract| Volume 45, SUPPLEMENT 2, S52, November 2022

Effect of EphA2 silencing on inhibiting the progression of non-metastatic renal cell carcinoma in an orthotopic mouse model of renal cell carcinoma

Open AccessDOI:https://doi.org/10.1016/S2666-1683(22)02455-7
Effect of EphA2 silencing on inhibiting the progression of non-metastatic renal cell carcinoma in an orthotopic mouse model of renal cell carcinoma
Previous ArticleEn-bloc vs. conventional resection of primary bladder tumor (eBLOC): A multicenter, open-label, phase 3 randomised controlled trial
Next ArticleRisk of residual teratoma after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumor and IGCCCG intermediate/poor prognosis: A multi-institutional retrospective cohort study
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S2666-1683(22)02455-7

      Copyright

      © 2022 European Association of Urology. Published by Elsevier B.V. Published by Elsevier Inc.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX